Osteogenesis Imperfecta
The Position of Substitution for Glycine by Cysteine in the Triple Helical Domain of the Proα1(I) Chains of Type I Collagen Determines the Clinical Phenotype

Barbra J. Starman,* David Eyre,† Harry Charbonneau,§ Maria Harrylock,∥ Mary Ann Weis,∥ Lester Weiss,∥ John M. Graham, Jr.,∥ and Peter H. Byers* TT

Departments of *Pathology, †Orthopedics, §Biochemistry, and **Medicine, and #the Center for Inherited Disease, University of Washington, Seattle, Washington 98195; †Henry Ford Hospital, Detroit, Michigan 48202; and
∥Child Development Center, Dartmouth University, Hanover, New Hampshire 03755

Abstract
Skin fibroblasts grown from three individuals with osteogenesis imperfecta (OI) each synthesized a population of normal type I collagen molecules and additional molecules that had one or two α1(I) chains that contained a cysteine residue within the triple-helical domain, a region from which cysteine normally is excluded. The patients had very different phenotypes. One patient with OI type I had a population of α1(I) chains in which glycine at position 94 of the triple helix was substituted by cysteine; a patient with OI type III had a population of α1(I) chains in which glycine at position 526 of the triple helix was substituted by cysteine; and the third patient, with OI type II, had a cysteine for glycine substitution at position 718 of the α1(I) chain. From all three patients, molecules that contained two mutant chains formed interchain, intramolecular disulfide bonds, and although less stable to thermal denaturation than normal molecules, they were more stable than molecules that contained only a single mutant chain. These findings indicate that substitutions for glycine within the triple-helical domain of the α1(I) chain are not invariably lethal and that their phenotypic effect largely depends on the nature of the substituting residue and its location in the chain.

Introduction
Osteogenesis imperfecta (OI)1 is a remarkably heterogeneous disorder with phenotypes that range from lethal in the perinatal period to mild, virtually asymptomatic conditions (1, 2). A variety of molecular defects have been found to cause OI, including gene rearrangements (3–6), point mutations (7–10), genomic deletions or splicing mutations that result in deletion of single exon sequences from the mature mRNA and thus the protein (11, 12), mutations that alter the reading frame in the gene for either chain of type I procollagen (13,2 and mutations

1. Abbreviations used in this paper: OI, osteogenesis imperfecta.

Dr. Graham’s present address is Ahmanson Pediatric Center, Medical Genetics and Birth Defects Center, Cedars-Sinai Medical Center, UCLA School of Medicine, Los Angeles, CA 90048.
Address correspondence to Dr. Peter H. Byers, Department of Pathology SM-30, University of Washington, Seattle, WA 98195.
Received for publication 11 April 1989 and in revised form 15 June 1989.

0021-9738/89/10/1206/09 $2.00
Volume 84, October 1989, 1206–1214

Osteogenesis Imperfecta
The Position of Substitution for Glycine by Cysteine in the Triple Helical Domain of the Proα1(I) Chains of Type I Collagen Determines the Clinical Phenotype

Barbra J. Starman,* David Eyre,† Harry Charbonneau,§ Maria Harrylock,∥ Mary Ann Weis,∥ Lester Weiss,∥ John M. Graham, Jr.,∥ and Peter H. Byers* TT

Departments of *Pathology, †Orthopedics, §Biochemistry, and **Medicine, and #the Center for Inherited Disease, University of Washington, Seattle, Washington 98195; †Henry Ford Hospital, Detroit, Michigan 48202; and
∥Child Development Center, Dartmouth University, Hanover, New Hampshire 03755

Abstract
Skin fibroblasts grown from three individuals with osteogenesis imperfecta (OI) each synthesized a population of normal type I collagen molecules and additional molecules that had one or two α1(I) chains that contained a cysteine residue within the triple-helical domain, a region from which cysteine normally is excluded. The patients had very different phenotypes. One patient with OI type I had a population of α1(I) chains in which glycine at position 94 of the triple helix was substituted by cysteine; a patient with OI type III had a population of α1(I) chains in which glycine at position 526 of the triple helix was substituted by cysteine; and the third patient, with OI type II, had a cysteine for glycine substitution at position 718 of the α1(I) chain. From all three patients, molecules that contained two mutant chains formed interchain, intramolecular disulfide bonds, and although less stable to thermal denaturation than normal molecules, they were more stable than molecules that contained only a single mutant chain. These findings indicate that substitutions for glycine within the triple-helical domain of the α1(I) chain are not invariably lethal and that their phenotypic effect largely depends on the nature of the substituting residue and its location in the chain.

Introduction
Osteogenesis imperfecta (OI)1 is a remarkably heterogeneous disorder with phenotypes that range from lethal in the perinatal period to mild, virtually asymptomatic conditions (1, 2). A variety of molecular defects have been found to cause OI, including gene rearrangements (3–6), point mutations (7–10), genomic deletions or splicing mutations that result in deletion of single exon sequences from the mature mRNA and thus the protein (11, 12), mutations that alter the reading frame in the gene for either chain of type I procollagen (13,2 and mutations

1. Abbreviations used in this paper: OI, osteogenesis imperfecta.

Dr. Graham’s present address is Ahmanson Pediatric Center, Medical Genetics and Birth Defects Center, Cedars-Sinai Medical Center, UCLA School of Medicine, Los Angeles, CA 90048.
Address correspondence to Dr. Peter H. Byers, Department of Pathology SM-30, University of Washington, Seattle, WA 98195.
Received for publication 11 April 1989 and in revised form 15 June 1989.

0021-9738/89/10/1206/09 $2.00
Volume 84, October 1989, 1206–1214
cysteine (1.010 Ci/mM; both from Amersham Corp., Arlington Heights, IL) under conditions previously described (17, 18). Medium and cell-layer proteins were harvested separately in the presence of protease inhibitors (17, 18) and concentrated by ethanol precipitation (30% vol/vol) after addition of carrier collagen (25 μg/ml; Sigma Chemical Co., St. Louis, MO). Digestion of procollagen with pepsin (50 μg/ml; Boehringer Mannheim Biochemicals, Inc., Indianapolis, IN) was carried out for 2 h at 18°C in 0.5 M acetic acid adjusted to pH 2.0 with HCl. The reaction was stopped by the addition of pepstatin and lyophilization.

Characterization of collagen by SDS-PAGE

Procollagen chains were separated under reducing conditions in 5% acrylamide slab gels containing SDS and 2 M urea (17, 19); collagens were separated in the same gels under nonreducing conditions. In some experiments proteins separated in one dimension were cleaved in the gel with cyanogen bromide and the resultant peptides were analyzed by electrophoresis in a second dimension gel (18).

Determination of thermal stability

Thermal stability of pepsin-digested procollagens was determined as previously described (17, 18, 20).

Preparation of sample for determination of partial amino acid sequence

To prepare collagen chains for microsequence analysis, 10 100-mm dishes (Corning Glass Works, Corning, NY) were grown to confluence and proteins were labeled with [3H]proline the first day and with [35S]cysteine the next day using conditions outlined above except that no carrier collagen was added to the harvested medium. The medium was collected, dialyzed into 30 mM Tris-HCl, 20 mM NaCl, 2 M urea, pH 7.6, at 4°C, applied to a DEAE-cellulose column (DE-52, 12 × 150 mm; Whatman Laboratory Products Inc., Clifton, NJ) in the same buffer, and eluted with a 300-ml linear gradient from 0 to 100 mM NaCl (21). Type I procollagen was dialyzed into 10 mM NH₄HCO₃ and lyophilized.

The methods for isolating the fragment of the triple-helical domain of the α1(I) chain that contained the cysteine residue differed slightly with each mutation. In the first family the type I procollagen was cleaved with pepsin, the cysteine residues in the α chains were modified with 4-vinyl pyridine (22), and the chains were separated by reverse-phase HPLC (23, 24). The α1(I) chains were collected, dried, and then cleaved with trypsin and the 35S-containing α1(I)CB5 peptide was recovered by a second HPLC step. This peptide was digested with trypsin (sequencing

Figure 1. Radiograph of the proband in family 2. There are multiple wormian bones in the skull, the ribs are thin without evidence of previous fracture, the femurs are short and bowed, and the tibias are bowed.

Biochemical–Clinical Correlation in Osteogenesis Imperfecta 1207
grade; Boehringer Mannheim Biochemicals, Inc.) in 0.1 M NH4HCO3, and the resulting 35S-containing fragment was again isolated by reverse-phase HPLC. The peptide was then dried and subjected to Edman degradation using a gas-phase automated sequencer (model 470A; Applied Biosystems Inc., Foster City, CA). A portion of the output at each cycle was analyzed on line for PTH-amino acids (model 120A online PTH analyzer; Applied Biosystems Inc.) and the remainder was collected to determine the content of radioactivity by scintillation counting.

In the second family the cysteines in the isolated proa chains of type I procollagen were reduced and carboxymethylated with iodoacetate after reduction for 4 h in 8 M urea with DTT. Sodium iodoacetate was added to a final concentration of 20 mM and after 15 min a fresh aliquot of DTT was added and the sample was dialyzed into 0.1 M acetic acid before lyophilization. The dried sample was digested with cyanogen bromide for 24 h and the resulting peptides were separated by reverse-phase HPLC (see below for details). The tubes that contained a1(I)CB3 were pooled and dried. Purified a1(I)CB3 was cleaved at the single Asn-Gly bond in the peptide with hydroxyamine (25). The sample was dissolved in water and warmed to 40°C, an equal volume of cold 2 M NH3OH, pH 10.5, was added, and the mixture was incubated at 35°C for 90 min. The sample was then frozen before separation of the fragments. The new peptides were resolved by HPLC (see below) and the 35S-containing fragment was identified by liquid scintillation counting. The labeled fragment was dried and subjected to automated peptide sequence analysis. For the first eight cleavages 80% of the sample was committed to identification of PTH-amino acids and the remainder was monitored by liquid scintillation counting; the entire sample was counted for products of cleavages 9–29.

After purification of type I procollagen synthesized by the cells in the patient family 3, the molecules were cleaved with pepsin and the cysteine residues in the a chains were reduced with DTT and alkylated with 4-vinyl pyridine. The chains were cleaved with cyanogen bromide and a1(I)CB3 was separated by reverse-phase HPLC. The peptide was then cleaved with trypsin and the fragment that contained 35S was isolated by reverse-phase HPLC and then subjected to sequence determination as above.

**Separation of peptides by HPLC**

Whole a chains and peptides obtained from type I procollagen after cleavage with cyanogen bromide and cleavage of a1(I)CB3 with hydroxyamine were dissolved in 1% trifluoroacetic acid and separated by reverse-phase chromatography on C4, C8, or C18 macroporous columns. The starting solvent, A, consisted of 5% (vol/vol) acetonitrile in 0.1% (vol/vol) trifluoroacetic acid. Solvent B consisted of 3:1 (vol/vol) acetonitrile/n-propanol in 0.1% trifluoroacetic acid. Whole a1(I) chains were separated on a Brownlee Aquapore RP-300 column (C8; 25 cm × 4.6 mm; Applied Biosystems Inc.) or a 214TP54 column (C4; 25 cm × 4.6 mm; Vydac, Hesperia, CA) by a gradient of 15–30% B in 50 min. Cyanogen bromide peptides were separated by a linear gradient of 5–15% B in 40 min (a1[I]CB5, family 1), or a complex gradient of 8–30% B in 60 min (a1[I]CB3, family 2; a1[I]CB7, family 3) on the Brownlee RP-300 column. Hydroxyamine peptides were separated by a linear 0–25% B gradient over a period of 40 min. Tryptic peptides were resolved on the same column using a linear gradient of 0–30% B in 60 min. All column effluents (1 ml/min) were monitored for absorbance at 220 nm, and for 1H and 35S radioactivity by liquid scintillation counting.

**Results**

**Cysteine in the a1(I) chain of type I collagen.** Dermal fibroblasts cultured from two of the three probands (probands from families 2 and 3) synthesized normal type I procollagen and type I procollagen whose chains had delayed electrophoretic mobility when examined by SDS-PAGE under reducing conditions (Fig. 2 A). The delay in mobility was abolished by incubation of cells in α,α'-dipyridyl to block prolyl and lysyl hydroxylation (not shown). In the third proband, the individual from family 1, we did not identify any alteration in mobility or in the efficiency of secretion of type I procollagen. When the amino- and carboxyl-terminal propeptides of type I procollagen were removed by cleavage with pepsin and the products were examined by SDS-PAGE in the absence of reduction of disulfide bonds, there was in each cell strain a band that migrated between the a1(I) chains and the trimer of a1(III) that was not synthesized by control cells or by cells from unaffected family members. The electrophoretic mobilities of the new band differed slightly with each cell strain. In all three cases the new chain migrated with chains in the region of a1(I) under reducing conditions (not shown). In addition, in the

![Figure 2. Proα and α chains synthesized by cells from family 1 (A), family 2 (B), and the proband in family 3 (C). In each group proα chains separated under reducing conditions are in the top panel and collagen chains separated under nonreducing conditions are in the bottom panel. In the bottom panel of each a new band is visible that migrates between a1(I) and a1(III); the mobility of the band differs in each patient. In A (top panel) the two OI panels are from the affected mother and one daughter (the proband); the control (C) is a nonfamily control. In the bottom panel only the proteins synthesized by the daughter's cells are shown. In B and C, OI, affected; F, unaffected father; M, unaffected mother; C, control.](image)

1208  Starman, Eyre, Charbonneau, Harrylock, Weis, Weiss, Graham, and Byers
samples from families 2 and 3 there was a band that migrated just slower than the normal $\alpha 1(I)$ (Fig. 2 B). The amount of the abnormal band that remained within the cells differed among the three cell strains; there was virtually none in the cells from the proband in family 1 and increasing amounts in the probands from families 2 and 3, respectively.

Localization of the new cysteine residues in $\alpha 1(I)$. To characterize the abnormal bands synthesized by cells from the probands, we separated the pepsin-treated $[^3H]$proline-labeled collagenous proteins in the first dimension under nonreducing conditions, cleaved the proteins in the gel with cyanogen bromide, and examined the peptides in a second dimension gel under nonreducing and reducing conditions. When the peptides were separated under reducing conditions, in each case the band that migrated between $\alpha 1(I)$ chains and the ($\alpha 1[III]$)$_2$ molecules gave rise to the peptides of $\alpha 1(I)$ (Fig. 3). Under nonreducing conditions the expected peptides from the new chain synthesized by cells from the proband in family 1 were all present but the partial fragment $\alpha 1(I)$CB5-8 was missing (residues 86–401; Fig. 3 A), which suggested that the cysteine was in the domain of $\alpha 1(I)$CB5.

When the peptides from the $\alpha 1(I)$ dimer synthesized by the cells grown from the proband in family 2 were separated under nonreducing conditions all the peptides except $\alpha 1(I)$CB3 were present and an additional band of about the size of a dimer of $\alpha 1(I)$CB3 was evident (Fig. 3 B, left panel). When the peptides were separated under reducing conditions in the second dimension, all the peptides of $\alpha 1(I)$, including $\alpha 1(I)$CB3, were seen (Fig. 3 B, right panel). This indicated that the abnormal molecules synthesized by the proband contained a cysteine residue in the domain of $\alpha 1(I)$CB3 (triple-helical residues 402–551), a region from which cysteine is normally excluded.

The electrophoretic mobility of $\alpha 1(I)$CB7, $\alpha 1(I)$CB8, and $\alpha 1(I)$CB6 from the dimer were normal; that of $\alpha 1(I)$CB3 was delayed. In contrast, the electrophoretic mobilities of $\alpha 1(I)$CB8 and $\alpha 1(I)$CB3 derived from the band that migrated slightly slower than $\alpha 1(I)$ were delayed, while those of $\alpha 1(I)$CB7 and $\alpha 1(I)$CB6 were normal. These findings suggested that in this cell strain overmodification extended over a longer domain in molecules that contained a single mutant chain than in molecules that contained two mutant chains joined by a disulfide bond.

To better localize the new cysteine residue in proband 2, we separated $[^3S]$cysteine-labeled $\alpha$ chains in the first dimension by SDS-PAGE, cleaved them in the gel with hydroxyamine, and separated the resulting peptides in the second dimension. The major cysteine-containing band migrated more slowly than $\alpha 1(I)$CB7 (271 residues) and more rapidly than the partial cleavage fragment $\alpha 1(I)$CB7-6 (463 residues; not shown). This placed the new cysteine residue in both the $\alpha 1(I)$CB3 fragment (residues 402–551) and the large hydroxyamine fragment (residues 523–980) and located it between residues 523 and 551.

When the peptides from the $\alpha 1(I)$ dimer synthesized by cells from the proband in family 3 were examined under nonreducing conditions all the peptides except for $\alpha 1(I)$CB7 were identified (Fig. 3 C). The peptides from the slowly migrating $\alpha 1(I)$ chain all migrated more slowly than those from the normal chain except for $\alpha 1(I)$CB6, the carboxyl-terminal peptide of the triple-helical domain. These results indicated that overmodification of the chains in abnormal molecules began in $\alpha 1(I)$CB7 and extended to the amino-terminal end of the molecule and that the new cysteine was situated between residues 552 and 822.

Figure 3. Cyanogen bromide peptides from the normal and abnormal chains and the $\alpha 1(I)$ dimer synthesized by cells from the probands in families 1 (A), 2 (B), and 3 (C). $[^3H]$Proline-labeled procollagen secreted by cells from the proband were digested with pepsin and the $\alpha$ chains were separated in the first dimension under nonreducing conditions and cleaved in the gel with cyanogen bromide; the peptides were then separated in the second dimension under nonreducing conditions. For the right panel in B the peptides were separated under reducing conditions in the second dimension. The position of the new band in the first dimension gel is marked with an asterisk. A. Peptides from the dimer separated under nonreducing conditions show no evidence of the partial cleavage fragment $\alpha 1(I)$CB5-8. This locates the cysteine in $\alpha 1(I)$CB5. B. Under nonreducing conditions (left panel) $\alpha 1(I)$CB3 from the dimer (asterisk) is not seen but a new band is present above $\alpha 1(I)$CB5-8 (arrow). Under reducing conditions $\alpha 1(I)$CB3 is present (arrow), although the electrophoretic mobility is slower than that of the normal $\alpha 1(I)$CB3. These findings indicate that the new cysteine is in $\alpha 1(I)$CB3. C. Under nonreducing conditions there is a new fragment from the $\alpha 1(I)$ dimer that migrates near the position of $\alpha 2(1)$CB3-5 and all the peptides with the exception of $\alpha 1(I)$CB6 are overmodified. This indicates that the cysteine is located amino-terminal to $\alpha 1(I)$CB6 in the domain of $\alpha 1(I)$CB7. A diagrammatic representation of the cyanogen bromide peptides of the triple-helical domain of the $\alpha 1(I)$ chain is located below.
Identification of substituted residues. We then labeled procollagens with \(^{3}H\)proline and \(^{35}S\)cysteine, purified type I procollagen by DEAE-cellulose chromatography, isolated by HPLC the cysteine-containing fragments created by chemical and/or enzymatic cleavage, and determined the radioactive and, when possible, the chemical sequence of the fragments. In this manner we determined that in family 1 the cysteine replaced glycine at position 94 of the triple helix of the \(\alpha(1)(I)\) chain, in proband 2 the cysteine replaced glycine at position 526 of the triple helix of the \(\alpha(1)(I)\) chain, and in proband 3 the cysteine replaced glycine at position 718 of the triple helix of the \(\alpha(1)(I)\) chain (Fig. 4). In the collagens synthesized by the probands in families 1 and 3 the site of the cysteine for glycine substitutions was revealed by coincident \(^{35}S\) radioactivity and the PTH derivative of pyridinylethyl cysteine together with a major running sequence for the tryptic peptide. In the peptide sequences around the mutant site in families 2 and 3 the proline that preceeded the cysteine appeared to be fully hydroxylated considering the PTH amino acid yield.

Abnormal molecules have a low thermal stability. In all three cell strains in which there is a cysteine for glycine substitution, the type I procollagen molecules that contained two abnormal chains (as evidenced by the presence of interchain disulfide bonds) melted at lower temperatures than control molecules, but at higher temperatures than those molecules that contained only a single abnormal chain (Fig. 5). In collagens synthesized by cells from proband 1, molecules that contained the disulfide bonded \(\alpha(1)(I)\) dimer melted between 41 and 42°C, and the abnormal molecules that contained a single abnormal chain melted between 39 and 40°C; in those from proband 2, the dimer melted between 40 and 41°C, and the molecules that contained a single abnormal chain melted at \(\sim 39.5°C\); in those from proband 3, the dimer melted between 37 and 38°C and the molecules that contained a single abnormal chain melted at \(\sim 37°C\). In each instance the single mutant chain (cysteine labeled) in the abnormal molecules was susceptible to proteolysis at a lower temperature than the normal chain (proline labeled) that had become overmodified.

Discussion
We have identified three separate families in which the presence of a cysteine residue within the triple-helical domain of the pro\(\alpha(1)(I)\) chain of type I procollagen results in an OI phenotype. The clinical result of the mutations is strikingly different: glycine to cysteine at residue 94 of the triple helix results in the mild OI type I phenotype; glycine to cysteine at residue 526 results in the moderate OI type III phenotype; and glycine to cysteine at residue 718 results in the perinatal lethal OI type II phenotype.

The marked clinical heterogeneity in OI has been difficult to explain clearly on the basis of biochemical findings. The mildest dominantly inherited form, OI type I, often results from mutations that alter the amount of normal type I procollagen secreted by cultured cells (14–16). Rarely, it may result from deletion of all of COL1A1 allele (Willing, M. C., and P. H. Byers, unpublished observations), but more commonly appears to result from a variety of other mutations that affect the synthesis of pro\(\alpha(1)(I)\) chains (14–16), the incorporation of pro\(\alpha(1)(I)\) chains into type I procollagen, the rapid intracellular degradation of abnormal type I procollagen molecules, or evidence of an altered sequence within the telopeptide domain of the \(\alpha(1)(I)\) chain (26); linkage of the phenotype to mutations in both COL1A1 and COL1A2 is consistent with these biochemical and molecular genetic findings (27, 28).

In most instances the perinatal lethal form, OI type II, results from substitutions for single glycyl residues within the triple helical domain of \(\alpha(1)(I)\) or \(\alpha(2)(I)\). These mutations appear to interfere with the formation of stable triple helix, delay secretion of molecules that contain mutant chains, alter the extent of posttranslational modification of all chains in molecules that carry a defective chain (17), interfere with amino-terminal propeptide cleavage, and result in an abnormal structure of type I procollagen molecules that may affect fibrillogenesis (29). In rare instances the OI type II phenotype may result from mutations that result in deletion or insertion of coding material (3–6).
Figure 5. Thermal stability of the collagen molecules synthesized by cells from the probands in families 1 (A), 2 (B), and 3 (C). Proteins analyzed in each top panel were biosynthetically labeled with $[^{3}H]$proline and those in the bottom were labeled with $[^{35}S]$cysteine. In B, lane 1 of the top panel contains $[^{35}S]$cysteine-labeled proteins and lane 1 of the bottom panel contains $[^{3}H]$proline-labeled proteins to confirm the position of the cysteine-labeled proteins.

Between these extremes lies a large group of individuals with OI, classified on clinical grounds as either OI type III (progressive deforming) or OI type IV (dominantly inherited with non-blue sclerae and often accompanied by dentinogenesis imperfecta) and ranging in severity from mild to moderately severe (1, 2). Relatively few mutations that produce these disorders have been identified. A 4-bp deletion near the 3' end of the coding region of the proα2(I) chain that altered the last 12 residues of the chain and prevented its assembly into type I procollagen molecules produced an OI type III phenotype in the homozygous state but had little phenotypic effect in the heterozygotes (13, 30). Deletion of single exons encoding domains near the amino-terminal end of the triple helix of the proα2(I) chain (11) or near the center of the triple helix (31) have produced mild-to-moderate phenotypes, as has a substitution of arginine for glycine near the carboxyl-terminal end of the triple-helical domain of proα2(I) (32). This list, however, emphasizes the difficulty in providing a cohesive understanding of the genotype-phenotype relationship in the mild-to-moderate OI phenotypes.

We think that our findings in the three families studied here, in addition to the accumulation of mutations rapidly being identified, begin to help understand some aspects of the relationships between mutation and phenotype. It is striking that there is progressive improvement of phenotype as the same point mutation, substitution of cysteine for glycine,
Table 1. Sequences around Known Cysteine for Glycine Substitutions in the Proα1(I) Chains of Type I Procollagen

<table>
<thead>
<tr>
<th>Sequence</th>
<th>Position</th>
</tr>
</thead>
<tbody>
<tr>
<td>AlaGlyProHypGlyPheHypGlyAlaValGlyAlaLysCysGluAlaGlyProGlnGlyProArgGlySerGlyProGlnGlyValArg</td>
<td>175</td>
</tr>
<tr>
<td>ThrGlyProAlaGlyArgHypGlyGluValGlyProHypCysProHypGlyProAlaGlyLysGluGlyGlySerHypGlyAlaAspGlyProAla</td>
<td>748</td>
</tr>
<tr>
<td>ThrGlyProAlaGlyProAlaGlyProValGlyProAlaCysAlaArgGlyProAlaGlyGlnGlyProArgGlyAspGlyGluThr</td>
<td>904</td>
</tr>
<tr>
<td>AspGlyLeuAsnGlyLeuHypGlyProlleGlyProHypCysProArgGlyArgThrGlyAspGlyProValGlyProHypGlyProHyp</td>
<td>988</td>
</tr>
</tbody>
</table>

The mutant sequences are compiled from the following sources: cysteine for glycine at residues 94, 526, and 718 (this report); 175; 748 (8); 904 (34); 988 (7). The substitution at 94 procedures the OI type I phenotype; the substitution at 175 produces clinical variability (33) but largely OI type IV; the substitution at 526 produces OI type III; the substitutions at 718, 748, 904, and 988 all produce the OI type II lethal phenotype.

moves toward the amino-terminal end of the triple helix of the proα1(I) chain. This movement is accompanied by increased efficiency of secretion of molecules that contain abnormal chains, increased thermal stability of those molecules, and decreased extent along the molecule in which overmodification occurs. Because cysteine is normally excluded from the triple-helical domain of proα1(I), substitutions in the chain can be identified by the formation of an α1(I) chain dimer. Lethal point mutations have been identified that result in substitutions of cysteine for glycine at positions 988 (7), 904 (33), and 748 (8) in the triple-helical domain, and a milder form results from substitution for glycine at position 175 (34). These families fit the generalization that mutations that result in substitution of cysteine for glycine are more severe in their phenotypic consequences when they occur near the carboxyl-terminal end of the triple-helical domain of proα1(I) than at the amino-terminal end.

This end-rule or phenotypic gradient for mutations along the proα1(I) chain probably depends on the nature of the substituting amino acid. We are aware, for example, that substitution of arginine for glycine at positions 391 (9) or 664 (10) results in a lethal OI phenotype and that substitution for glycine by arginine at position 154 results in the OI type III phenotype. Inspection of the sequence motifs around the lethal and nonlethal cysteine for glycine substitutions (Table I) does not clearly identify specific domains which, when altered, produce lethal phenotypes. For example, the substitutions at 718 and 748 both disrupt the hexapeptide GlyProHypGlyProHyp and are lethal. The substitution at 988 substitutes a glycine that succeeds a potentially hydroxylatable prolyl residue and the substitution is in a region bounded by additional hydroxyproline residues. In contrast, the substitution at 904 is in a region entirely devoid of hydroxyproline and would ordinarily be considered a relatively loose triple-helical domain. The nonlethal substitutions at 94 and 175 are in regions that are not rich in hydroxyproline and would probably be considered intermediate in stability. The substitution at 526 succeeds a hydroxylatable prolyl residue and is embedded in a region of moderate hydroxyproline content; if hydroxyproline content alone determined the phenotype, then this would be considered a candidate for a lethal mutation. Given these considerations, it appears that the nature of the substitution and its location in the chain are the major determinants of the phenotypic outcome of a point mutation. Because cysteine residues in the triple-helical domains of fibrillar collagens, in contrast to other substitutions, have the potential for covalent interactions with other molecules within the cell and in the matrix, cysteine substitutions may differ in their effects from those of other residues.

The prolyl residues that preceded the new cysteines in the abnormal α1(I) chains synthesized by cells from the probands in families 1 (position 93) and family 3 (position 717) were hydroxylated. These observations suggest that prolyl 4-hydroxylase may recognize general context as well as specific sequence.

The stability to thermal denaturation of the chains in molecules that contained one mutant and one normal α1(I) chain were not equivalent and the first proteolytic cleavage appeared in the abnormal chain. The sequences around the mutation sites in each chain we characterized include basic residues that would be cleaved by the trypsin in the incubation mixture (Table I). Our observations suggest that the conformation of the single mutant chain is altered more than that of the two normal chains and, further, that the disulfide bond created in molecules with two abnormal chains acts to stabilize those chains in a less available conformation.

Finally, the findings in family 2 have an additional important implication in that they confirm that the OI type III phenotype can result from dominant mutations that result in substitutions for glycine residues in the triple helix of the α1(I) chain of type I collagen. Until now, clinical genetic (2, 35) and

3. Hollister, D., personal communication.
biochemical studies (13) have been interpreted to indicate that this form of OI is usually inherited in an autosomal recessive fashion. The findings in this family, additional sequence determination, and our survey of individuals with moderately severe OI phenotypes (Wenstrup, R. J., M. C. Welling, B. J. Starman, and P. H. Byers, manuscript submitted for publication) all suggest that a significant proportion of individuals with the OI type III clinical phenotype result from dominant mutations which, in some families, are inherited.

Acknowledgments

We thank the families for their cooperation, Dr. Golder Wilson for supplying additional clinical information about family 2, Dr. Barbara McMillivray and Dr. Derek Applegarth for supplying clinical information and the cultured fibroblasts from the proband in family 3, Carole Rainer and Kathy Braun for assistance with cell culture and sample preparation, Stephen Apone for help with HPLC, Robert Underwood for photography and figure preparation, and David Hollister for providing sequence information before publication. This research was supported in part by grants from the National Institutes of Health (AR-21557, GM-15253, AR-37318, and GM-15731) and a Clinical Research Grant (6-298) from the March of Dimes Birth Defects Foundation.

References


α1 chain produces a kink at this site in the procollagen I molecule and an altered N-proteinase cleavage site over 225 nm away. J. Biol. Chem. 263:19249–19255.


